



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
1662/51203

Application Number
10/730,949

Filing Date
December 10, 2003

Examiner
Not Yet Assigned

Art Unit
1614

Title
A METHOD FOR SYNTHESIZING
LEFLUNOMIDE

Applicant(s)
Ilya AVRUTOV et al.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on
Date: 4/30/04 Reg. No. 54,567

Signature: _____

Dana Ziker

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies are enclosed of each patent, publication or other information listed on the modified PTO Form 1449 marked with an asterisk. Otherwise, copies of each patent, publication or other information listed on the modified PTO Form 1449 are not enclosed since they were previously cited by or submitted to the Patent Office in a prior application, Serial No. 09/779,928, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: _____

4-30-04

By: _____

Dana Ziker

Dana Ziker (Reg. No. 54,567)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1662/51203	U.S. SERIAL NO. 10/730,949
	APPLICANT Ilya AVRUTOV et al.	
	FILING DATE December 10, 2003	GROUP 1614



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	4,284,786	August 18, 1981	KÄMMERER et al.			
	4,892,963	January 9, 1990	GALLAGHER et al.			
	5,610,173	March 11, 1997	Schwartz et al.			
	5,783,592	July 21, 1998	Schwartz et al.			
	6,303,792	October 16, 2001	Lau et al.			
	*6,221,891	April 24, 2001	Faasch et al.			
	*6,610,718	August 26, 2003	Avrutow et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 013 376 A	July 23, 1980	Europe			Abst.	
	EP 0 607 775 A	July 27, 1994	Europe			Abst.	
	WO 00/50411	August 31, 2000	PCT			X	
	WO 91/17748	November 28, 1991	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Bertolini, Giorgio et al. "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, A Potent Immunosuppressive Drug" <i>Journal of Medicinal Chemistry</i> , American Chemical Society. Washington, US, vol. 13, no. 40, 1997, pages 2011-2016.
	Doleschall, G., Seres, P., <i>J. Chem. Soc. Perkin Trans. I</i> , 1988, 1875-1879.
	Fossa, P., Menozza, G., Schenone, P., <i>Il Farmaco</i> , 1991, 46, 789-802.
	*Bartlett, R.R. et al.: "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection" <i>Agents and Actions</i> , 1991, vol. 32, N°1/2, pages 10-21.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	